List view / Grid view
26 August 2013 | By Novartis
Novartis has invited 60 selected students from leading international universities in 21 countries to its headquarters in Switzerland for the International Biotechnology Leadership Camp...
26 August 2013 | By AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a definitive agreement to acquire Amplimmune...
25 August 2013 | By Amgen
Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash...
23 August 2013 | By GlaxoSmithKline
The first of four Phase III studies, the SHIELD-1 study, investigating vercirnon in adult patients with moderately-to-severely active Crohn’s disease did not achieve the primary endpoint...
21 August 2013 | By kdm communications limited
Corresponding with the 60th Anniversary of the Association for Clinical Biochemistry, Abbott recently hosted an enthusiastically received session at the Annual ACB FOCUS National Meeting held in York, entitled The Diamond Generation; Pathology begins at 60...
21 August 2013 | By Abbott
Abbott has completed its acquisition of IDEV Technologies, a privately held company focused on developing next-generation medical devices...
20 August 2013 | By METTLER TOLEDO
Whether you work with simple or complex samples, guaranteeing the correct results is important...
20 August 2013 | By Novartis
Novartis announced that the US FDA has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM)...
19 August 2013 | By Packer Forbes Communications
The EMA has granted an update to the marketing authorisation for Tyverb® (lapatinib) to be used in combination with Herceptin® (trastuzumab)...
19 August 2013 | By Abbott
Abbott has completed its acquisition of OptiMedica Corporation, a privately-held, Silicon Valley-based ophthalmic device company...
19 August 2013 | By Johnson & Johnson
Late-stage prostate cancer treatment strengthens oncology pipeline..
15 August 2013 | By OgilvyHealthPR London
Data published in The Lancet showed that elderly people with Type 2 Diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin, marketed by Boehringer Ingelheim and Eli Lilly and Company, experienced significant reductions in blood glucose levels (HbA1c) compared with those receiving placebo. In addition, the…
15 August 2013 | By Boehringer Ingelheim
Boehringer Ingelheim announced that enrolment of over 950 treatment naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso™ 1 and 2 trials is complete...
15 August 2013 | By Novartis
The Australian Therapeutic Goods Administration (TGA) has added Bexsero® to the Australian Register of Therapeutic Goods (ARTG)...
14 August 2013 | By GlaxoSmithKline
“Today’s announcement is important for women with this specific type of metastatic breast cancer..."
